Continued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 26 million sales milestone payments to Basilea
- 53 LR
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal infections, reported today that sales of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer in Europe and the Asia Pacific and China regions, respectively, exceeded thresholds that triggered two separate milestone payments totaling USD 26.25 million to Basilea.
- Under the terms of the agreement, Basilea remains eligible for milestone payments of up to approximately CHF 515 million, in addition to receiving mid-teen royalties on net sales.
- Cresemba has been approved in 73 countries to date and is currently marketed in 67 countries, including the United States, most EU member states and additional countries inside and outside of Europe.
- In 2022, total global in-market sales of Cresemba amounted to USD 373 million, a 15 percent growth year-on-year.1